FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Glenmark Pharmaceuticals Atomoxetine Capsules Recall

Atomoxetine Capsules, USP, 25 mg, 30 capsule bottles, Rx Only, Manufactured for: Norths…

Glenmark Pharmaceuticals Inc., USA · Mahwah, NJ

Risk level
Class II
Reported by FDA
Feb 26, 2025
Recall ID
D-0240-2025
Check your lot numberHow we source this data

Summary

Glenmark Pharmaceuticals recalled Atomoxetine Capsules starting Jan 29, 2025. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0240-2025 on Feb 26, 2025. Reason: CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit. Status: Ongoing.

Why it was recalled

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Product description

Atomoxetine Capsules, USP, 25 mg, 30 capsule bottles, Rx Only, Manufactured for: Northstar Rx LLC., Memphis, TN 38141, Manufactured by: Glenmark Pharmaceuticals Ltd., Goa, India, NDC 16714-757-01.

Lot numbers, UPCs & expiration codes

Lot Numbers: 19232506, 19232397, 19232415, Exp.: 5/2025; 19233791, Exp.: 8/2025; 19234248, Exp.: 9/2025; 19240909, Exp.: 2/2026; 19242598, Exp.:6/2026; 19243163, 19243122, Exp.: 7/2026; 19243884, Exp.: 9/2026.

Where it was sold

Nationwide within the U.S

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0240-2025
Classification
Class II
Status
Ongoing
Recall initiated
Jan 29, 2025
FDA report date
Feb 26, 2025
Quantity
133,824 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Glenmark Pharmaceuticals Inc., USA

Original FDA data

Every field from FDA enforcement report D-0240-2025, exactly as published.

Show all FDA fields
City
Mahwah
State
NJ
Status
Ongoing
Country
United States
Event ID
96194
Address
750 Corporate Dr
Code information
Lot Numbers: 19232506, 19232397, 19232415, Exp.: 5/2025; 19233791, Exp.: 8/2025; 19234248, Exp.: 9/2025; 19240909, Exp.: 2/2026; 19242598, Exp.:6/2026; 19243163, 19243122, Exp.: 7/2026; 19243884, Exp.: 9/2026.
Postal code
07430-2009
Report date
Feb 26, 2025
Product type
Drugs
Recall number
D-0240-2025
Classification
Class II
Recalling firm
Glenmark Pharmaceuticals Inc., USA
Product quantity
133,824 bottles
Reason for recall
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Atomoxetine Capsules, USP, 25 mg, 30 capsule bottles, Rx Only, Manufactured for: Northstar Rx LLC., Memphis, TN 38141, Manufactured by: Glenmark Pharmaceuticals Ltd., Goa, India, NDC 16714-757-01.
Distribution pattern
Nationwide within the U.S
Recall initiation date
Jan 29, 2025
Initial firm notification
Letter
Center classification date
Feb 20, 2025

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0240-2025, published Feb 26, 2025. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls